Form 4: MapLight Therapeutics CSO Executes Stock Sale
Statement of Changes in Beneficial Ownership
Chief Scientific Officer James Woodruff sold 721 shares of MapLight Therapeutics common stock under a pre-arranged 10b5-1 trading plan.
Summary
- James Woodruff, Chief Scientific Officer of MapLight Therapeutics, sold 721 shares of voting common stock.
- The shares were sold at a weighted average price of $28.28 per share.
- The transaction occurred on May 7, 2026.
- Following the sale, the reporting person retains beneficial ownership of 242,729 shares.
- The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on December 29, 2025.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed via a pre-planned 10b5-1 program and represents a very small fraction of the executive's total holdings.
Positives
- The transaction was conducted under a pre-established Rule 10b5-1 trading plan, which is designed to avoid concerns regarding insider trading.
Negatives
- The sale represents a reduction in the equity stake held by a key member of the executive leadership team.
Risks
- Future sales by insiders could potentially signal a lack of confidence in the company's long-term growth prospects.
Future Outlook
No specific forward-looking guidance regarding company operations was provided in this filing.
Industry Context
StockSavvy.ai notes that routine insider selling under 10b5-1 plans is a standard corporate practice for liquidity and diversification, and generally does not reflect a change in management's outlook on the company's fundamental business performance.
Comparison to Industry Standards
- The use of Rule 10b5-1 plans is the industry standard for executives to manage personal equity holdings while maintaining regulatory compliance.
Stakeholder Impact
- Minimal impact on shareholders as the transaction was pre-planned and represents a negligible portion of the total outstanding shares.
Next Steps
- Continued monitoring of future Form 4 filings for additional insider activity.
Key Dates
| Date | Description |
|---|---|
| 2025-12-29 | Date the Rule 10b5-1 trading plan was adopted. |
| 2026-05-07 | Date of the reported stock sale transaction. |
| 2026-05-11 | Date the Form 4 was signed and filed. |
Keywords
MapLight Therapeutics, MPLT, Insider Trading, Form 4, Chief Scientific Officer, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.